Merck & Co. Inc.'s Keytruda (pembrolizumab) reached double digits for FDA-approved indications, with the agency most recently backing the programmed-death receptor for the treatment of gastric cancer.
Keytruda specifically gained accelerated approval Sept. 22 for the treatment of patients with recurrent locally advanced or metastatic gastric or...








